Seek truth from facts, competitive symbiosis
Several drugs from the Zhengqing Group have secured both registration and production approvals as well as clinical trial approvals.
Category:
Release time:
2026-03-06
Recently, our company’s pharmaceutical R&D and registration efforts have achieved a major breakthrough: four drugs have successfully obtained registration and production approvals from the National Medical Products Administration, and one drug has secured clinical trial approval, showcasing the company’s strength in drug development and its sustained innovative capabilities, while injecting strong momentum into the company’s high‑quality development.
Registration Production Batch Approval:
Esomeprazole enteric‑coated capsules (available in 20 mg and 40 mg strengths);
Haloperidol raw material;
Miloride topical solution;
Nafamostat mesylate raw material.
Clinical Approval:
Nafamostat Mesylate for Injection (available in 5 mg and 10 mg strengths)
The approval of multiple drugs this time is the result of the company’s long‑term dedication to pharmaceutical R&D and its rigorous quality control measures. This not only enriches the company’s product portfolio and expands its business scope, but also provides clinicians with more safe and effective treatment options, helping to elevate the standard of care for related diseases and enabling the company to serve society with higher‑quality products while benefiting patients.
In the future, the company will continue to increase its R&D investment, accelerate the development, production, and launch of various pharmaceutical products, stay true to its original commitment to quality, deepen its expertise in the pharmaceutical and healthcare sector, and drive the enterprise toward higher‑quality growth.
Copyright Hunan Zhengqing Pharmaceutical Group Co., Ltd.
Virtual Showroom：
Agent：
OA：
CRM：
在线客服添加返回顶部
右侧在线客服样式 1,2,3 1
图片alt标题设置： Hunan Zhengqing Pharmaceutical Group Co., Ltd.
表单验证提示文本： Please enter correct content!
循环体没有内容时： Updating......
CSS / JS 文件放置地